Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $58000.0.

  • Axsome Therapeutics' Capital Expenditures fell 3555.56% to $58000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $439000.0, marking a year-over-year increase of 7773.28%. This contributed to the annual value of $270000.0 for FY2024, which is 5360.82% down from last year.
  • Axsome Therapeutics' Capital Expenditures amounted to $58000.0 in Q3 2025, which was down 3555.56% from $13000.0 recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Capital Expenditures ranged from a high of $371000.0 in Q3 2023 and a low of $7000.0 during Q4 2023
  • Moreover, its 4-year median value for Capital Expenditures was $90000.0 (2024), whereas its average is $130866.7.
  • The largest annual percentage gain for Axsome Therapeutics' Capital Expenditures in the last 5 years was 46212.12% (2023), contrasted with its biggest fall of 9613.26% (2023).
  • Quarter analysis of 4 years shows Axsome Therapeutics' Capital Expenditures stood at $181000.0 in 2022, then plummeted by 96.13% to $7000.0 in 2023, then soared by 328.57% to $30000.0 in 2024, then surged by 93.33% to $58000.0 in 2025.
  • Its Capital Expenditures was $58000.0 in Q3 2025, compared to $13000.0 in Q2 2025 and $338000.0 in Q1 2025.